Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
BOSTON, Dec. 21, 2020 – Atea Pharmaceuticals (Nasdaq: AVIR) announces that CEO Jean-Pierre Sommadossi will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 a.m. ET. A live webcast will be available on the company’s website, with a replay for 90 days thereafter.
Atea focuses on developing antiviral therapeutics for severe viral infections including COVID-19, dengue, HCV, and RSV, utilizing a proprietary purine nucleotide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) has been added to the Russell 2000 Index, effective December 21, 2020. This inclusion is part of the index's quarterly IPO additions and is expected to broaden the company's investor base and increase awareness of its antiviral therapies, especially AT-527 for COVID-19 treatment. The Russell indexes, benchmarked by around $9 trillion in assets, are crucial for investment managers and institutional investors.
Atea Pharmaceuticals (Nasdaq: AVIR) announced management's participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 12:35 p.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days afterward.
Specializing in antiviral therapeutics, Atea focuses on developing treatments for severe viral infections, including COVID-19, hepatitis C, dengue, and RSV, leveraging their proprietary nucleotide and nucleoside prodrug platform.
Atea Pharmaceuticals has appointed Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. Duncan brings extensive financial and public company expertise, having held senior roles at various biopharmaceutical firms, including Chief Financial Officer at Intercept Pharmaceuticals. Her appointment comes at a crucial time as Atea transitions to a publicly traded company and aims to advance its antiviral pipeline, particularly the oral COVID-19 treatment, AT-527. This strategic leadership change is expected to enhance Atea's market navigation and therapeutic development efforts.
Atea Pharmaceuticals (Nasdaq: AVIR) announced the closure of its initial public offering, raising a total of $345 million by selling 14,375,000 shares at $24.00 each. This includes the complete exercise of the underwriters' overallotment option, adding an additional $45 million. The stock began trading on the Nasdaq Global Select Market on October 30, 2020. Major underwriters included J.P. Morgan and Morgan Stanley.
Atea Pharmaceuticals has priced its initial public offering at $24.00 per share, offering 12,500,000 shares to the public, expected to generate $300 million in gross proceeds. The common stock will begin trading on Nasdaq under the ticker symbol AVIR on October 30, 2020, with the closing of the offering anticipated on November 3, 2020. The underwriters have a 30-day option to purchase an additional 1,875,000 shares. J.P. Morgan, Morgan Stanley, Evercore, and William Blair are the joint book-running managers.